Technology Platforms

Noxopharm is an innovative biotechnology company with a science driven strategy to advance the most promising life-saving therapies for patients with cancer or inflammatory diseases, through the discovery, preclinical and clinical phases.

The company's focus is on adding value to its assets at each step of the process.

It has three separate drug development programs:

Chroma™ is a technology platform focused on the development of multiple drug candidates, primarily for cancer treatment.
The Sofra™ technology platform has a pipeline of new proprietary drugs based on oligonucleotides, the building blocks of DNA or RNA, with a focus on the treatment of autoimmune and inflammatory diseases.
Veyonda® is Noxopharm’s clinical drug candidate, currently in global phase 1 and 2 clinical trials for the treatment of a range of cancers.